About: Nathalie Chaput-Gras

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Nathalie Chaput-Gras Goto Sponge NotDistinct Permalink

An Entity of Type : foaf:Person, within Data Space : data.idref.fr associated with source document(s)

Attributes	Values
type	Person
sameAs	Chaput-Gras, Nathalie (1974-.... ; Membre du jury d'une thèse de doctorat en Immunologie) Chaput-Gras, Nathalie (1974-.... ; Membre du jury d'une thèse de doctorat en Immunologie) Chaput-Gras, Nathalie (1974-.... ; Membre du jury d'une thèse de doctorat en Immunologie) Chaput-Gras, Nathalie (1974-.... ; Membre du jury d'une thèse de doctorat en Immunologie)
alternative label	Chaput, Nathalie
Life Event	http://www.idref.fr/078701473/birth
preferred label	Chaput-Gras, Nathalie (1974-.... ; Membre du jury d'une thèse de doctorat en Immunologie)
name	Nathalie Chaput-Gras
dbpedia-owl:citizenship	http://sws.geonames.org/3017382/
Language	http://lexvo.org/id/iso639-3/fra
isni:identifierValid	000000013958913X
Given name	Nathalie
familyName	Chaput-Gras
has biographical i...tion (Deprecated)	Docteur en pharmacie et Docteur en sciences médicales. PU-PH – Immunologie Clinique, Institut Gustave Roussy, université Paris-Saclay (en 2021)
gender	female
ORCID iD	0000-0003-3968-8669
Scopus ID	6506134138
is sameAs of	Chaput-Gras, Nathalie (1974-.... ; Membre du jury d'une thèse de doctorat en Immunologie) Chaput-Gras, Nathalie (1974-.... ; Membre du jury d'une thèse de doctorat en Immunologie) Chaput-Gras, Nathalie (1974-.... ; Membre du jury d'une thèse de doctorat en Immunologie) Chaput-Gras, Nathalie (1974-.... ; Membre du jury d'une thèse de doctorat en Immunologie)
is Thesis advisor of	http://www.sudoc.fr/180019465/id Etude des réponses lymphocytaires T CD4 anti-tumorales, de l'identification de cibles à leur utilisation pour l'immunomonitorage http://www.sudoc.fr/22169983X/id http://www.sudoc.fr/182078299/id http://www.sudoc.fr/198606079/id http://www.sudoc.fr/175115362/id http://www.sudoc.fr/192745778/id http://www.sudoc.fr/200069500/id http://www.sudoc.fr/240463439/id http://www.sudoc.fr/276687329/id http://www.sudoc.fr/261734148/id http://www.sudoc.fr/260127035/id http://www.sudoc.fr/267501730/id http://www.sudoc.fr/26075840X/id http://www.sudoc.fr/26963570X/id http://www.sudoc.fr/27867870X/id http://www.sudoc.fr/280988516/id
is Praeses of	http://www.sudoc.fr/19806411X/id http://www.sudoc.fr/221472568/id http://www.sudoc.fr/267596847/id http://www.sudoc.fr/235152609/id http://www.sudoc.fr/26144929X/id http://www.sudoc.fr/224981536/id http://www.sudoc.fr/260078069/id http://www.sudoc.fr/259761494/id http://www.sudoc.fr/268706484/id http://www.sudoc.fr/273046713/id http://www.sudoc.fr/279509278/id
is Author of	http://www.sudoc.fr/078700833/id http://www.sudoc.fr/088669599/id Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors? Deep phenotyping of immune cell populations by optimized and standardized flow cytometry analyses Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab Killer dendritic cells: IKDC and the others. Genomic Instability and Pro-Tumoral Inflammation are associated with Primary Resistance to Anti-PD1 + Anti-Angiogenesis in Malignant Pleural Mesothelioma The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2. http://hub.abes.fr/libbey/periodical/journaldepharmacieclinique/2019/volume_38/issue_3/CE05BF6267464A50E053120B220A94A5/w Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N) Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. http://www.sudoc.fr/25956480X/id ‬Immunogénicité des exosomes de cellules dendritiques et implications en immunothérapie antitumorale Contribution of IL-17-producing {gamma}{delta} T cells to the efficacy of anticancer chemotherapy. Enterocolitis due to immune checkpoint inhibitors: a systematic review Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study Baseline gut microbiota in metastatic melanoma patients treated with ipilimumab: Relation with clinical response and colitis New oxazaphosphorine prodrug’s for immunotherapy and n anomedicine against cancer Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Trans-presentation of IL-15 dictates IFN-producing killer dendritic cells effector functions. Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade Human leukocyte antigen (HLA) class I/II expression as a predictive biomarker for response to immune oncology (IO) therapy in metastatic clear-cell renal cell carcinoma (m-ccRCC) Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora? Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Dendritic cells and innate defense against tumor cells. Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities NIVOREN GETUG-AFU 26 translational study: Baseline peripheral cytokines predict survival in metastatic clear cell renal carcinoma (RCC) treated with nivolumab The potential of exosomes in immunotherapy of cancer https://serval.unil.ch/notice/serval:BIB_8382F8338941#id Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Interleukin‐7/Interferon axis drives T‐cell and salivary gland epithelial cell interactions in Sjögren’s syndrome Combined strategy based on pre-activated analogs of oxazaphosphorines for increased therapeutic index and immune modulation Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. Dendritic Cell-Derived Exosomes Promote Natural Killer Cell Activation and Proliferation: A Role for NKG2D Ligands and IL-15Rα http://hub.abes.fr/libbey/periodical/hepatogastrooncologiedigestive/2018/volume_25/issue_3/CE05BF62641E4A50E053120B220A94A5/w Estimating causal effects of time-dependent exposures on a binary endpoint in a high-dimensional setting https://serval.unil.ch/notice/serval:BIB_6FF32E9F7C2B#id http://id.erudit.org/iderudit/013491ar#id Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15Rα and NKG2D Triggering IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment The dendritic cell-like functions of IFN-producing killer dendritic cells reside in the CD11b+ subset and are licensed by tumor cells.

Faceted Search & Find service v1.13.91 as of Aug 16 2018

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of May 14 2019, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (70 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software